{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:13:32Z","timestamp":1791213212215,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T00:00:00Z","timestamp":1421280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s10555-014-9542-0","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T07:46:05Z","timestamp":1421221565000},"page":"115-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Immunotherapy of melanoma: Present options and future promises"],"prefix":"10.1007","volume":"34","author":[{"given":"Anand","family":"Rotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Bhandaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"McElwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,15]]},"reference":[{"issue":"1","key":"9542_CR1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","volume":"355","author":"AJ Miller","year":"2006","unstructured":"Miller, A. J., & Mihm, M. C., Jr. (2006). Melanoma. New England Journal of Medicine, 355(1), 51\u201365. doi: 10.1056\/NEJMra052166 .","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"9542_CR2","first-page":"11","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63(1), 11\u201330. doi: 10.3322\/caac.21166 .","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3\u20134","key":"9542_CR3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10555-013-9433-9","volume":"32","author":"Y Cheng","year":"2013","unstructured":"Cheng, Y., Zhang, G., & Li, G. (2013). Targeting MAPK pathway in melanoma therapy. Cancer and Metastasis Reviews, 32(3\u20134), 567\u2013584. doi: 10.1007\/s10555-013-9433-9 .","journal-title":"Cancer and Metastasis Reviews"},{"issue":"3","key":"9542_CR4","first-page":"171","volume":"64","author":"V Saranga-Perry","year":"2014","unstructured":"Saranga-Perry, V., Ambe, C., Zager, J. S., & Kudchadkar, R. R. (2014). Recent developments in the medical and surgical treatment of melanoma. CA: A Cancer Journal for Clinicians, 64(3), 171\u2013185. doi: 10.3322\/caac.21224 .","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"9542_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1741-7015-10-23","volume":"10","author":"L Finn","year":"2012","unstructured":"Finn, L., Markovic, S. N., & Joseph, R. W. (2012). Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 10, 23. doi: 10.1186\/1741-7015-10-23 .","journal-title":"BMC Medicine"},{"issue":"9","key":"9542_CR6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncponc1183","volume":"5","author":"FS Hodi","year":"2008","unstructured":"Hodi, F. S., Oble, D. A., Drappatz, J., Velazquez, E. F., Ramaiya, N., Ramakrishna, N., et al. (2008). CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nature Clinical Practice Oncology, 5(9), 557\u2013561. doi: 10.1038\/ncponc1183 .","journal-title":"Nature Clinical Practice Oncology"},{"issue":"8","key":"9542_CR7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S., O\u2019Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711\u2013723. doi: 10.1056\/NEJMoa1003466 .","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"9542_CR8","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert, C., Thomas, L., Bondarenko, I., O\u2019Day, S., Weber, J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517\u20132526. doi: 10.1056\/NEJMoa1104621 .","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"9542_CR9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","volume":"18","author":"MA Postow","year":"2013","unstructured":"Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N., Panageas, K. S., Lawrence, D. P., et al. (2013). Ipilimumab for patients with advanced mucosal melanoma. The Oncologist, 18(6), 726\u2013732. doi: 10.1634\/theoncologist. 2012-0464 .","journal-title":"The Oncologist"},{"issue":"12","key":"9542_CR10","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg, S. A. (2014). IL-2: the first effective immunotherapy for human cancer. Journal of Immunology, 192(12), 5451\u20135458. doi: 10.4049\/jimmunol.1490019 .","journal-title":"Journal of Immunology"},{"issue":"7","key":"9542_CR11","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology, 17(7), 2105\u20132116.","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"9542_CR12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrclinonc.2013.153","volume":"10","author":"HL Kaufman","year":"2013","unstructured":"Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S., Amatruda, T., Bines, S. D., et al. (2013). The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews. Clinical Oncology, 10(10), 588\u2013598. doi: 10.1038\/nrclinonc.2013.153 .","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"9542_CR13","first-page":"39","volume":"5","author":"S Okuyama","year":"2010","unstructured":"Okuyama, S., Gonzalez, R., & Lewis, K. D. (2010). Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review. Core Evidence, 5, 39\u201348.","journal-title":"Core Evidence"},{"issue":"4","key":"9542_CR14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1984.2.4.336","volume":"2","author":"JM Kirkwood","year":"1984","unstructured":"Kirkwood, J. M., & Ernstoff, M. S. (1984). Interferons in the treatment of human cancer. Journal of Clinical Oncology, 2(4), 336\u2013352.","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"9542_CR15","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.4049\/jimmunol.1290060","volume":"189","author":"AA Tarhini","year":"2012","unstructured":"Tarhini, A. A., Gogas, H., & Kirkwood, J. M. (2012). IFN-alpha in the treatment of melanoma. Journal of Immunology, 189(8), 3789\u20133793. doi: 10.4049\/jimmunol.1290060 .","journal-title":"Journal of Immunology"},{"issue":"10","key":"9542_CR16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1634\/theoncologist.2012-0123","volume":"17","author":"TM Herndon","year":"2012","unstructured":"Herndon, T. M., Demko, S. G., Jiang, X., He, K., Gootenberg, J. E., Cohen, M. H., et al. (2012). U.S. food and drug administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. The Oncologist, 17(10), 1323\u20131328. doi: 10.1634\/theoncologist. 2012-0123 .","journal-title":"The Oncologist"},{"issue":"7","key":"9542_CR17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","volume":"12","author":"J Weber","year":"2007","unstructured":"Weber, J. (2007). Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. The Oncologist, 12(7), 864\u2013872. doi: 10.1634\/theoncologist.12-7-864 .","journal-title":"The Oncologist"},{"issue":"12","key":"9542_CR18","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/eji.1830181206","volume":"18","author":"P Dariavach","year":"1988","unstructured":"Dariavach, P., Mattei, M. G., Golstein, P., & Lefranc, M. P. (1988). Human Ig superfamily CTLA-4 gene: Chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. European Journal of Immunology, 18(12), 1901\u20131905. doi: 10.1002\/eji.1830181206 .","journal-title":"European Journal of Immunology"},{"issue":"2","key":"9542_CR19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1084\/jem.184.2.783","volume":"184","author":"NJ Karandikar","year":"1996","unstructured":"Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., & Bluestone, J. A. (1996). CTLA-4: a negative regulator of autoimmune disease. Journal of Experimental Medicine, 184(2), 783\u2013788.","journal-title":"Journal of Experimental Medicine"},{"issue":"6","key":"9542_CR20","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","volume":"183","author":"TL Walunas","year":"1996","unstructured":"Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996). CTLA-4 ligation blocks CD28-dependent T cell activation. Journal of Experimental Medicine, 183(6), 2541\u20132550.","journal-title":"Journal of Experimental Medicine"},{"issue":"14","key":"9542_CR21","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 100(14), 8372\u20138377. doi: 10.1073\/pnas.1533209100 .","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"9542_CR22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine, 369(2), 122\u2013133. doi: 10.1056\/NEJMoa1302369 .","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"9542_CR23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.febslet.2013.10.015","volume":"588","author":"C Kyi","year":"2014","unstructured":"Kyi, C., & Postow, M. A. (2014). Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters, 588(2), 368\u2013376. doi: 10.1016\/j.febslet.2013.10.015 .","journal-title":"FEBS Letters"},{"issue":"5","key":"9542_CR24","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","volume":"2","author":"DF McDermott","year":"2013","unstructured":"McDermott, D. F., & Atkins, M. B. (2013). PD-1 as a potential target in cancer therapy. Cancer Medicine, 2(5), 662\u2013673. doi: 10.1002\/cam4.106 .","journal-title":"Cancer Medicine"},{"issue":"1","key":"9542_CR25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.critrevonc.2013.08.002","volume":"89","author":"B Merelli","year":"2014","unstructured":"Merelli, B., Massi, D., Cattaneo, L., & Mandala, M. (2014). Targeting the PD1\/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology\/Hematology, 89(1), 140\u2013165. doi: 10.1016\/j.critrevonc.2013.08.002 .","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"6","key":"9542_CR26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou, W., & Chen, L. (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 8(6), 467\u2013477. doi: 10.1038\/nri2326 .","journal-title":"Nature Reviews Immunology"},{"issue":"8","key":"9542_CR27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., et al. (2007). PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer, 109(8), 1499\u20131505. doi: 10.1002\/cncr.22588 .","journal-title":"Cancer"},{"issue":"49","key":"9542_CR28","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., et al. (2004). Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 101(49), 17174\u201317179. doi: 10.1073\/pnas.0406351101 .","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"9542_CR29","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","volume":"13","author":"T Nomi","year":"2007","unstructured":"Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., et al. (2007). Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer. Clinical Cancer Research, 13(7), 2151\u20132157. doi: 10.1158\/1078-0432.CCR-06-2746 .","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"9542_CR30","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., et al. (2007). Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3360\u20133365. doi: 10.1073\/pnas.0611533104 .","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"21","key":"9542_CR31","first-page":"7462","volume":"63","author":"S Wintterle","year":"2003","unstructured":"Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., et al. (2003). Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 63(21), 7462\u20137467.","journal-title":"Cancer Research"},{"issue":"10","key":"9542_CR32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology, 32(10), 1020\u20131030. doi: 10.1200\/JCO.2013.53.0105 .","journal-title":"Journal of Clinical Oncology"},{"issue":"9948","key":"9542_CR33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., et al. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 384(9948), 1109\u20131117. doi: 10.1016\/S0140-6736(14)60958-2 .","journal-title":"Lancet"},{"issue":"1","key":"9542_CR34","doi-asserted-by":"crossref","first-page":"e27255","DOI":"10.4161\/onci.27255","volume":"3","author":"LJ Thomas","year":"2014","unstructured":"Thomas, L. J., He, L. Z., Marsh, H., & Keler, T. (2014). Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. Oncoimmunology, 3(1), e27255. doi: 10.4161\/onci.27255 .","journal-title":"Oncoimmunology"},{"issue":"2","key":"9542_CR35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1189\/jlb.0610351","volume":"89","author":"J Denoeud","year":"2011","unstructured":"Denoeud, J., & Moser, M. (2011). Role of CD27\/CD70 pathway of activation in immunity and tolerance. Journal of Leukocyte Biology, 89(2), 195\u2013203. doi: 10.1189\/jlb.0610351 .","journal-title":"Journal of Leukocyte Biology"},{"key":"9542_CR36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2051-1426-2-7","volume":"2","author":"DA Schaer","year":"2014","unstructured":"Schaer, D. A., Hirschhorn-Cymerman, D., & Wolchok, J. D. (2014). Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. Journal of Immunotherapy Cancer, 2, 7. doi: 10.1186\/2051-1426-2-7 .","journal-title":"Journal of Immunotherapy Cancer"},{"issue":"14","key":"9542_CR37","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-11-3308","volume":"18","author":"LA Vitale","year":"2012","unstructured":"Vitale, L. A., He, L. Z., Thomas, L. J., Widger, J., Weidlick, J., Crocker, A., et al. (2012). Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clinical Cancer Research, 18(14), 3812\u20133821. doi: 10.1158\/1078-0432.CCR-11-3308 .","journal-title":"Clinical Cancer Research"},{"key":"9542_CR38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005). The B7 family revisited. Annual Review of Immunology, 23, 515\u2013548. doi: 10.1146\/annurev.immunol.23.021704.115611 .","journal-title":"Annual Review of Immunology"},{"issue":"7","key":"9542_CR39","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/eji.200839028","volume":"39","author":"J Leitner","year":"2009","unstructured":"Leitner, J., Klauser, C., Pickl, W. F., Stockl, J., Majdic, O., Bardet, A. F., et al. (2009). B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. European Journal of Immunology, 39(7), 1754\u20131764. doi: 10.1002\/eji.200839028 .","journal-title":"European Journal of Immunology"},{"issue":"3","key":"9542_CR40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., et al. (2001). B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nature Immunology, 2(3), 269\u2013274. doi: 10.1038\/85339 .","journal-title":"Nature Immunology"},{"issue":"14","key":"9542_CR41","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","volume":"18","author":"D Loo","year":"2012","unstructured":"Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., et al. (2012). Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clinical Cancer Research, 18(14), 3834\u20133845. doi: 10.1158\/1078-0432.CCR-12-0715 .","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"9542_CR42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1194\/jlr.R200019-JLR200","volume":"44","author":"DL Daleke","year":"2003","unstructured":"Daleke, D. L. (2003). Regulation of transbilayer plasma membrane phospholipid asymmetry. Journal of Lipid Research, 44(2), 233\u2013242. doi: 10.1194\/jlr. R200019-JLR200 .","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"9542_CR43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000315102","volume":"26","author":"F Lang","year":"2010","unstructured":"Lang, F., Gulbins, E., Lang, P. A., Zappulla, D., & Foller, M. (2010). Ceramide in suicidal death of erythrocytes. Cellular Physiology and Biochemistry, 26(1), 21\u201328. doi: 10.1159\/000315102 .","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"1\u20133","key":"9542_CR44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000334163","volume":"33","author":"F Lang","year":"2012","unstructured":"Lang, F., & Qadri, S. M. (2012). Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purification, 33(1\u20133), 125\u2013130. doi: 10.1159\/000334163 .","journal-title":"Blood Purification"},{"issue":"4","key":"9542_CR45","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1172\/JCI1112","volume":"101","author":"VA Fadok","year":"1998","unstructured":"Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998). Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine\/paracrine mechanisms involving TGF-beta, PGE2, and PAF. Journal of Clinical Investigation, 101(4), 890\u2013898. doi: 10.1172\/JCI1112 .","journal-title":"Journal of Clinical Investigation"},{"issue":"21","key":"9542_CR46","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.1158\/1078-0432.CCR-11-1074","volume":"17","author":"DE Gerber","year":"2011","unstructured":"Gerber, D. E., Stopeck, A. T., Wong, L., Rosen, L. S., Thorpe, P. E., Shan, J. S., et al. (2011). Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research, 17(21), 6888\u20136896. doi: 10.1158\/1078-0432.CCR-11-1074 .","journal-title":"Clinical Cancer Research"},{"key":"9542_CR47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2051-1426-2-11","volume":"2","author":"HL Kaufman","year":"2014","unstructured":"Kaufman, H. L., Ruby, C. E., Hughes, T., & Slingluff, C. L., Jr. (2014). Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. Journal of Immunotherapy Cancer, 2, 11. doi: 10.1186\/2051-1426-2-11 .","journal-title":"Journal of Immunotherapy Cancer"},{"issue":"2","key":"9542_CR48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi, Y., Liu, C. H., Roberts, A. I., Das, J., Xu, G., Ren, G., et al. (2006). Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know. Cell Research, 16(2), 126\u2013133. doi: 10.1038\/sj.cr.7310017 .","journal-title":"Cell Research"},{"issue":"5566","key":"9542_CR49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P Matzinger","year":"2002","unstructured":"Matzinger, P. (2002). The danger model: a renewed sense of self. Science, 296(5566), 301\u2013305. doi: 10.1126\/science.1071059 .","journal-title":"Science"},{"issue":"5","key":"9542_CR50","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1084\/jem.176.5.1453","volume":"176","author":"C Traversari","year":"1992","unstructured":"Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., et al. (1992). A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. Journal of Experimental Medicine, 176(5), 1453\u20131457.","journal-title":"Journal of Experimental Medicine"},{"issue":"5038","key":"9542_CR51","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","volume":"254","author":"P Bruggen van der","year":"1991","unstructured":"van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254(5038), 1643\u20131647.","journal-title":"Science"},{"issue":"12","key":"9542_CR52","doi-asserted-by":"crossref","first-page":"e26621","DOI":"10.4161\/onci.26621","volume":"2","author":"F Aranda","year":"2013","unstructured":"Aranda, F., Vacchelli, E., Eggermont, A., Galon, J., Sautes-Fridman, C., Tartour, E., et al. (2013). Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology, 2(12), e26621. doi: 10.4161\/onci.26621 .","journal-title":"Oncoimmunology"},{"issue":"6","key":"9542_CR53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2174\/156652311798192860","volume":"11","author":"T Murakami","year":"2011","unstructured":"Murakami, T., & Sunada, Y. (2011). Plasmid DNA gene therapy by electroporation: Principles and recent advances. Current Gene Therapy, 11(6), 447\u2013456.","journal-title":"Current Gene Therapy"},{"key":"9542_CR54","doi-asserted-by":"crossref","unstructured":"USDA licenses DNA vaccine for treatment of melanoma in dogs (2010). J Am Vet Med Assoc, 236(5), 495, doi: 10.2460\/javma.236.5.488 .","DOI":"10.2460\/javma.236.5.488"},{"issue":"21","key":"9542_CR55","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","volume":"24","author":"PJ Bergman","year":"2006","unstructured":"Bergman, P. J., Camps-Palau, M. A., McKnight, J. A., Leibman, N. F., Craft, D. M., Leung, C., et al. (2006). Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine, 24(21), 4582\u20134585. doi: 10.1016\/j.vaccine.2005.08.027 .","journal-title":"Vaccine"},{"issue":"4","key":"9542_CR56","first-page":"1284","volume":"9","author":"PJ Bergman","year":"2003","unstructured":"Bergman, P. J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., et al. (2003). Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research, 9(4), 1284\u20131290.","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"9542_CR57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. Nature Reviews Cancer, 12(4), 265\u2013277. doi: 10.1038\/nrc3258 .","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"9542_CR58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1755-148X.2008.00532.x","volume":"22","author":"S Marsafy El","year":"2009","unstructured":"El Marsafy, S., Bagot, M., Bensussan, A., & Mauviel, A. (2009). Dendritic cells in the skin\u2014Potential use for melanoma treatment. Pigment Cell & Melanoma Research, 22(1), 30\u201341. doi: 10.1111\/j.1755-148X.2008.00532.x .","journal-title":"Pigment Cell & Melanoma Research"},{"key":"9542_CR59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.coi.2014.01.005","volume":"27","author":"KJ Radford","year":"2014","unstructured":"Radford, K. J., Tullett, K. M., & Lahoud, M. H. (2014). Dendritic cells and cancer immunotherapy. Current Opinion in Immunology, 27, 26\u201332. doi: 10.1016\/j.coi.2014.01.005 .","journal-title":"Current Opinion in Immunology"},{"issue":"2","key":"9542_CR60","first-page":"1137","volume":"27","author":"M Kobayashi","year":"2007","unstructured":"Kobayashi, M., Suzuki, K., Yashi, M., Yuzawa, M., Takayashiki, N., & Morita, T. (2007). Tumor infiltrating dendritic cells predict treatment response to immunotherapy in patients with metastatic renal cell carcinoma. Anticancer Research, 27(2), 1137\u20131141.","journal-title":"Anticancer Research"},{"issue":"2","key":"9542_CR61","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/039463200702000212","volume":"20","author":"O Simonetti","year":"2007","unstructured":"Simonetti, O., Goteri, G., Lucarini, G., Rubini, C., Stramazzotti, D., Lo Muzio, L., et al. (2007). In melanoma changes of immature and mature dendritic cell expression correlate with tumor thickness: an immunohistochemical study. International Journal of Immunopathology and Pharmacology, 20(2), 325\u2013333.","journal-title":"International Journal of Immunopathology and Pharmacology"},{"issue":"7","key":"9542_CR62","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014). Clinical use of dendritic cells for cancer therapy. Lancet Oncology, 15(7), e257\u2013e267. doi: 10.1016\/S1470-2045(13)70585-0 .","journal-title":"Lancet Oncology"},{"issue":"7","key":"9542_CR63","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/1078-0432.CCR-10-2272","volume":"17","author":"J Weber","year":"2011","unstructured":"Weber, J., Atkins, M., Hwu, P., Radvanyi, L., Sznol, M., & Yee, C. (2011). White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clinical Cancer Research, 17(7), 1664\u20131673. doi: 10.1158\/1078-0432.CCR-10-2272 .","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"9542_CR64","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tibtech.2011.04.009","volume":"29","author":"TS Park","year":"2011","unstructured":"Park, T. S., Rosenberg, S. A., & Morgan, R. A. (2011). Treating cancer with genetically engineered T cells. Trends in Biotechnology, 29(11), 550\u2013557. doi: 10.1016\/j.tibtech.2011.04.009 .","journal-title":"Trends in Biotechnology"},{"issue":"5","key":"9542_CR65","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11912-012-0257-5","volume":"14","author":"S Lee","year":"2012","unstructured":"Lee, S., & Margolin, K. (2012). Tumor-infiltrating lymphocytes in melanoma. Current Oncology Reports, 14(5), 468\u2013474. doi: 10.1007\/s11912-012-0257-5 .","journal-title":"Current Oncology Reports"},{"issue":"6","key":"9542_CR66","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1189\/jlb.0513301","volume":"95","author":"WJ Urba","year":"2014","unstructured":"Urba, W. J. (2014). At the bench: Adoptive cell therapy for melanoma. Journal of Leukocyte Biology, 95(6), 867\u2013874. doi: 10.1189\/jlb.0513301 .","journal-title":"Journal of Leukocyte Biology"},{"issue":"13","key":"9542_CR67","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","volume":"70","author":"A Boni","year":"2010","unstructured":"Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M., et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research, 70(13), 5213\u20135219. doi: 10.1158\/0008-5472.CAN-10-0118 .","journal-title":"Cancer Research"},{"issue":"5","key":"9542_CR68","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","volume":"18","author":"JS Wilmott","year":"2012","unstructured":"Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., et al. (2012). Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386\u20131394. doi: 10.1158\/1078-0432.CCR-11-2479 .","journal-title":"Clinical Cancer Research"},{"issue":"16","key":"9542_CR69","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-11-2837","volume":"72","author":"RC Koya","year":"2012","unstructured":"Koya, R. C., Mok, S., Otte, N., Blacketor, K. J., Comin-Anduix, B., Tumeh, P. C., et al. (2012). BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Research, 72(16), 3928\u20133937. doi: 10.1158\/0008-5472.CAN-11-2837 .","journal-title":"Cancer Research"},{"issue":"31","key":"9542_CR70","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","volume":"30","author":"AM Eggermont","year":"2012","unstructured":"Eggermont, A. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H., Marsden, J., et al. (2012). Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. Journal of Clinical Oncology, 30(31), 3810\u20133818. doi: 10.1200\/JCO.2011.41.3799 .","journal-title":"Journal of Clinical Oncology"},{"key":"9542_CR71","author":"S Kelderman","year":"2014","unstructured":"Kelderman, S., Schumacher, T. N., & Haanen, J. B. (2014). Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology. doi: 10.1016\/j.molonc.2014.07.011 .","journal-title":"Molecular Oncology"},{"issue":"7","key":"9542_CR72","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2012.02.006","volume":"33","author":"L Baitsch","year":"2012","unstructured":"Baitsch, L., Fuertes-Marraco, S. A., Legat, A., Meyer, C., & Speiser, D. E. (2012). The three main stumbling blocks for anticancer T cells. Trends in Immunology, 33(7), 364\u2013372. doi: 10.1016\/j.it.2012.02.006 .","journal-title":"Trends in Immunology"},{"issue":"1","key":"9542_CR73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00424-011-1044-0","volume":"463","author":"L Besedovsky","year":"2012","unstructured":"Besedovsky, L., Lange, T., & Born, J. (2012). Sleep and immune function. Pfl\u00fcgers Archiv, 463(1), 121\u2013137. doi: 10.1007\/s00424-011-1044-0 .","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"4","key":"9542_CR74","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1037\/0033-2909.130.4.601","volume":"130","author":"SC Segerstrom","year":"2004","unstructured":"Segerstrom, S. C., & Miller, G. E. (2004). Psychological stress and the human immune system: a meta-analytic study of 30\u00a0years of inquiry. Psychological Bulletin, 130(4), 601\u2013630. doi: 10.1037\/0033-2909.130.4.601 .","journal-title":"Psychological Bulletin"},{"issue":"3","key":"9542_CR75","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.soncn.2013.06.007","volume":"29","author":"NA Kasparian","year":"2013","unstructured":"Kasparian, N. A. (2013). Psychological care for people with melanoma: what, when, why and how? Seminars in Oncology Nursing, 29(3), 214\u2013222. doi: 10.1016\/j.soncn.2013.06.007 .","journal-title":"Seminars in Oncology Nursing"},{"issue":"1","key":"9542_CR76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clindermatol.2011.11.005","volume":"31","author":"NA Kasparian","year":"2013","unstructured":"Kasparian, N. A. (2013). Psychological stress and melanoma: are we meeting our patients\u2019 psychological needs? Clinics in Dermatology, 31(1), 41\u201346. doi: 10.1016\/j.clindermatol.2011.11.005 .","journal-title":"Clinics in Dermatology"},{"issue":"9","key":"9542_CR77","first-page":"503","volume":"37","author":"C Fellner","year":"2012","unstructured":"Fellner, C. (2012). Ipilimumab (yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use. P T, 37(9), 503\u2013530.","journal-title":"P T"},{"issue":"9","key":"9542_CR78","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4161\/hv.21921","volume":"8","author":"B Jonsson","year":"2012","unstructured":"Jonsson, B., & Wilking, N. (2012). Cancer vaccines and immunotherapeutics: Challenges for pricing, reimbursement and market access. Human Vaccin Immunotherapy, 8(9), 1360\u20131363. doi: 10.4161\/hv.21921 .","journal-title":"Human Vaccin Immunotherapy"},{"issue":"5","key":"9542_CR79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/09546634.2013.813897","volume":"25","author":"C Ma","year":"2014","unstructured":"Ma, C., & Armstrong, A. W. (2014). Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. The Journal of Dermatological Treatment, 25(5), 401\u2013408. doi: 10.3109\/09546634.2013.813897 .","journal-title":"The Journal of Dermatological Treatment"},{"issue":"3","key":"9542_CR80","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","volume":"118","author":"SM Amos","year":"2011","unstructured":"Amos, S. M., Duong, C. P., Westwood, J. A., Ritchie, D. S., Junghans, R. P., Darcy, P. K., et al. (2011). Autoimmunity associated with immunotherapy of cancer. Blood, 118(3), 499\u2013509. doi: 10.1182\/blood-2011-01-325266 .","journal-title":"Blood"},{"issue":"1","key":"9542_CR81","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","volume":"71","author":"ME Lacouture","year":"2014","unstructured":"Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kahler, K. C., Busam, K. J., & Hauschild, A. (2014). Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology, 71(1), 161\u2013169. doi: 10.1016\/j.jaad.2014.02.035 .","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"9542_CR82","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","volume":"69","author":"K Minkis","year":"2013","unstructured":"Minkis, K., Garden, B. C., Wu, S., Pulitzer, M. P., & Lacouture, M. E. (2013). The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology, 69(3), e121\u2013e128. doi: 10.1016\/j.jaad.2012.12.963 .","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"9542_CR83","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CCO.0b013e328341edff","volume":"23","author":"MG Bouwhuis","year":"2011","unstructured":"Bouwhuis, M. G., Ten Hagen, T. L., Suciu, S., & Eggermont, A. M. (2011). Autoimmunity and treatment outcome in melanoma. Current Opinion in Oncology, 23(2), 170\u2013176. doi: 10.1097\/CCO.0b013e328341edff .","journal-title":"Current Opinion in Oncology"},{"issue":"Suppl 1 UCTN","key":"9542_CR84","first-page":"E308","volume":"46","author":"AM Hinds","year":"2014","unstructured":"Hinds, A. M., Ahmad, D. S., Muenster, J. E., Berg, Z. M., Lopez, K. T., Holly, J. S., et al. (2014). Ipilimumab-induced colitis: a rare but serious side effect. Endoscopy, 46(Suppl 1 UCTN), E308\u2013E309. doi: 10.1055\/s-0034-1377209 .","journal-title":"Endoscopy"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-014-9542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-014-9542-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-014-9542-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T20:23:08Z","timestamp":1651004588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-014-9542-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,15]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["9542"],"URL":"https:\/\/doi.org\/10.1007\/s10555-014-9542-0","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,15]]}}}